Bridge­Bio spins gold out of an Alex­ion castoff, scor­ing an FDA ap­proval in rare me­tab­o­lism dis­or­der

Now part of the fold at As­traZeneca, rare dis­ease spe­cial­ist Alex­ion doesn’t miss of­ten when it comes to tak­ing meds across the fin­ish line. But in one spe­cial case, Bridge­Bio took an Alex­ion castoff on board — and now it’s turned the drug in­to a win­ner.

The FDA ap­proved Bridge­Bio’s Nuli­bry (fos­denopterin), once known as ALXN1101, on Fri­day to treat molyb­de­num co­fac­tor de­fi­cien­cy type A, an au­to­so­mal re­ces­sive, in­born er­ror of me­tab­o­lism caused by mu­ta­tions in the molyb­de­num co­fac­tor syn­the­sis 1 gene (MOCS1).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER